William Blair Forecasts Lower Earnings for Ovid Therapeutics

Ovid Therapeutics Inc. (NASDAQ:OVID) – William Blair cut their Q2 2025 earnings estimates for shares of Ovid Therapeutics in a report released on Wednesday, March 12th. William Blair analyst S. Schram now expects that the company will earn ($0.15) per share for the quarter, down from their prior estimate of ($0.14). The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. William Blair also issued estimates for Ovid Therapeutics’ Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.61) EPS and FY2026 earnings at ($0.74) EPS.

Ovid Therapeutics (NASDAQ:OVID) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. The company had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.19 million. Ovid Therapeutics had a negative net margin of 5,142.56% and a negative return on equity of 39.24%.

A number of other research analysts have also commented on OVID. Oppenheimer raised Ovid Therapeutics from a “market perform” rating to an “outperform” rating and set a $4.00 price target for the company in a research report on Wednesday, January 29th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of Ovid Therapeutics in a research note on Wednesday, December 4th. Finally, Wedbush reissued an “outperform” rating and set a $3.00 price objective (down from $4.00) on shares of Ovid Therapeutics in a research report on Wednesday. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $3.20.

Ovid Therapeutics Stock Performance

Ovid Therapeutics stock opened at $0.43 on Friday. The company has a current ratio of 5.66, a quick ratio of 5.66 and a debt-to-equity ratio of 0.18. The firm has a market cap of $30.81 million, a P/E ratio of -0.92 and a beta of 0.29. Ovid Therapeutics has a 1-year low of $0.42 and a 1-year high of $3.45. The firm has a 50-day moving average of $0.65 and a 200-day moving average of $0.96.

Hedge Funds Weigh In On Ovid Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC increased its stake in shares of Ovid Therapeutics by 83.9% in the 4th quarter. SG Americas Securities LLC now owns 37,636 shares of the company’s stock worth $35,000 after acquiring an additional 17,172 shares in the last quarter. XTX Topco Ltd increased its stake in shares of Ovid Therapeutics by 46.2% during the third quarter. XTX Topco Ltd now owns 38,230 shares of the company’s stock valued at $45,000 after purchasing an additional 12,076 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Ovid Therapeutics by 49.7% during the fourth quarter. Bank of America Corp DE now owns 56,733 shares of the company’s stock valued at $53,000 after purchasing an additional 18,841 shares during the last quarter. FMR LLC lifted its holdings in shares of Ovid Therapeutics by 1,907.4% during the third quarter. FMR LLC now owns 50,225 shares of the company’s stock valued at $59,000 after purchasing an additional 47,723 shares during the last quarter. Finally, Velan Capital Investment Management LP bought a new stake in shares of Ovid Therapeutics in the 4th quarter worth approximately $65,000. Institutional investors own 72.24% of the company’s stock.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.